retatrutide mechanism glp-1 gip glucagon triple agonist review 2024 2025 Substack Series 3 of 6: – The Next Frontier in Longevity and Metabolic Health Glucagon-like peptide-1 receptor: mechanisms and

Evidence from Cardiovascular Outcome Trials (CVOTs) Multiple landmark clinical trials have firmly established the cardiovascular protective effects of GLP-1 receptor agonists (GLP-1 RAs), fundamentally altering treatment paradigms beyond diabetes management alone

Should I stop fiber supplements when I stop my GLP-1 medication

2018Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

As the cost of these medications comes down and more people recognize the long-term benefits of obesity treatment, we may start to see insurance companies changing their approach

Relative reductions in LFC at week 24 measured 14.0%, 56.3%, 75.2%, and 76.4%